Following the acquisition of Vernalis plc by Ligand Pharmaceuticals on 10th October 2018 , Vernalis is now a Ligand Company.
We are a world leader in structure- and fragment-based drug discovery. We have generated five development candidates in the past six years and cell active lead compounds against an additional nine different targets. Our successes include projects in close collaboration with companies such as Lundbeck, Novartis, Servier, Genentech, Asahi Kasei Pharma and Daiichi Sankyo. Our strengths are in developing and applying the most appropriate structure-based methods to work with our partners to solve problems in drug discovery.